Newron Pharmaceut. Stock
Price
Target price
€16.56
€16.56
-2.750%
-0.46
-2.750%
-
02.04.26 / Tradegate
WKN: A0LF18 / Name: Newron Pharmaceut. / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Newron Pharmaceut. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Newron Pharmaceut.
sharewise wants to provide you with the best news and tools for Newron Pharmaceut., so we directly link to the best financial data sources.
Financials
News
EQS-News: Newron presents 2025 financial results and provides 2026 outlook
EQS-News: Newron presents 2025 financial results and provides 2026 outlook
EQS-News: Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
EQS-News: Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
EQS-News: Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
EQS-News: Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
EQS-News: Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
EQS-News: Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
EQS-News: Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)